Search peptides, terms, sources/

Growth Hormone Research

Growth hormone research covers peptides studied for how they act on the growth-hormone-releasing hormone receptor or the ghrelin receptor, and for their effect on growth hormone release. Studies include human dose-escalation work, diagnostic trials in children and body-composition trials in specific groups. Evidence strength, age and regulatory history differ widely, so a shared mechanism does not mean equal evidence.

Which peptides have been studied in growth hormone research?

  • AOD-9604hGH Fragment 176-191

    Growth hormone fragment studied for weight management. Not licensed in the UK; its largest human trial showed no significant weight-loss benefit.

    Growth hormone axisHuman trialsEvidence reviewed
    ModerateNot licensed in the UK
  • CJC-1295CJC-1295 with DAC

    Long-acting growth-hormone-releasing hormone analogue studied for hormone levels in healthy adults. Not licensed in the UK; human evidence is small, short trials.

    Growth hormone axisHuman trialsEvidence reviewed
    LimitedNot licensed in the UK
  • GHRP-2Pralmorelin

    Synthetic hexapeptide that triggers growth hormone release. Not licensed in the UK; Japan licenses it only as a diagnostic test. No trial shows a health benefit.

    Growth hormone axisHuman trialsEvidence reviewed
    LimitedNot licensed in the UK
  • GHRP-6Growth hormone-releasing…

    Synthetic hexapeptide that triggers growth hormone release. Not licensed in the UK. Human studies are short hormone-response and diagnostic work; no trial shows a health benefit.

    Growth hormone axisHuman trialsEvidence reviewed
    LimitedNot licensed in the UK
  • HexarelinExamorelin

    Synthetic hexapeptide that triggers growth hormone release. Not licensed in the UK. In a long-term human study the response faded and IGF-I and body composition did not change.

    Growth hormone axisHuman trialsEvidence reviewed
    LimitedNot licensed in the UK
  • IpamorelinIPA

    Synthetic growth hormone secretagogue studied for growth hormone release. Not licensed in the UK; human evidence is one small pharmacokinetic study.

    Growth hormone axisHuman trialsEvidence reviewed
    LimitedNot licensed in the UK
  • SermorelinSermorelin acetate

    Synthetic growth-hormone-releasing hormone fragment studied in children with growth hormone deficiency. Not licensed in the UK; evidence is mainly from before 2000.

    Growth hormone axisHuman trialsEvidence reviewed
    LimitedNot licensed in the UK
  • TesamorelinTH9507

    Not licensed in the UK. Growth-hormone-releasing hormone analogue studied for visceral fat in HIV-associated lipodystrophy, in randomised trials.

    Growth hormone axisHuman trialsEvidence reviewed
    StrongNot licensed in the UK

View in the full index

Best recorded finding for each peptide in this area

The best recorded finding for each peptide in this area. Each row grades one finding, not the peptide or the medicine.
PeptideUK statusFindingStudy typeEvidence grade
CJC-1295Not licensed in the UKGrowth hormone and IGF-1 elevationHuman trialLimited
GHRP-2Not licensed in the UKAdult GH deficiency test, JapanHuman trialLimited
GHRP-6Not licensed in the UKPhase I pharmacokinetics, nine menHuman trialLimited
HexarelinNot licensed in the UKAmount-dependent GH, cortisol, prolactinHuman trialLimited
IpamorelinNot licensed in the UKHealthy male pharmacokinetic studyHuman trialLimited
SermorelinNot licensed in the UK1999 review, childhood GH deficiency—Limited

"Growth Hormone Research" covers peptides studied for their action on the growth-hormone-releasing hormone (GHRH) receptor or the ghrelin/GH-secretagogue receptor pathway, and their downstream effect on pituitary growth hormone release and circulating IGF-1. Research in this area includes human dose-escalation pharmacokinetic studies, diagnostic-use trials in paediatric growth-hormone deficiency, and body-composition trials in specific clinical populations. Peptides in this category differ considerably in the strength, age and regulatory history of their supporting evidence; inclusion reflects a shared mechanism of research interest, not equivalent evidence quality across peptides.

27 sources in the library relate to this area. See them.

Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.